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Key messages
Patient reported outcome data are increasingly being used by a range of
stakeholders in healthcare
These data may offer major benefits to patients and society, but current
use is fragmented and suboptimal
We propose an integrated evidence based approach to data collection to
meet multiple stakeholder needs
Over the past decade we have seen a global rise in the
involvement of patients in coproducing research and decisions
about their health and care. “Measuring what matters to patients”
is recognised as central to improving patient care and service
delivery, but patients need to be involved in deciding what to
measure and how.1
One way to measure what matters is using patient reported
outcome measures (PROMs), which are questionnaires
completed by patients to assess the effects of disease or
treatment (or both) on symptoms, functioning, and health related
quality of life from their perspective. PROM data can be used
to inform health technology assessment, pharmaceutical
labelling claims, health policy and service improvement, and
can support communication between patients and healthcare
professionals.2 3
Here we discuss the current applications and potential benefits
of PROMs in healthcare and challenges that reduce their
potential to drive improvements in patient care. We focus on
recent developments in the use of PROMs and consider
strategies for efficient PROM data collection to maximise
benefits for patients and society.
Current use and benefits
PROM assessment in research and routine clinical practice offers
a range of potential benefits for individual patient care and for
clinicians, regulators, healthcare management teams,
commissioners, and policy makers (table 1).
The use of PROMs in research, particularly in clinical trials and
observational studies, is well established and can provide
valuable evidence on the burden of disease and the efficacy,
effectiveness, and cost effectiveness of interventions from a
patient perspective.26 16 17 PROM data are increasingly being
used to provide evidence for drug and device approval. Emphasis
is being placed on involving patients throughout the innovation
pathway, including the appropriate collection of PROMs
informed by FDA and EMA guidance.27 28Aggregate PROM
data have been used in routine practice for several years; for
example, in the UK to assess provider performance in the
primary care Quality and Outcomes Framework (QOF)25 and
in the NHS PROMs initiative.2 29 Three PROMs (the PHQ9,
HADS, and Beck Depression Inventory-II) were used as part
of QOF to assess the severity of depression, to support clinical
decision making, and to assess provider performance. However,
the QOF indicator was dropped in 2013 owing to criticism
regarding over-diagnosis using the tools and the potential for
gaming.25 30 PROMs have been used to measure health gain in
patients undergoing hip or knee replacement, among other
procedures, based on responses to questionnaires before and
after surgery. Patients and referrers can use PROM data to help
decide where to receive treatment: NHS Choices publishes
provider level outlier data for PROM eligible procedures as part
of a “score card.”31 The evidence to support using PROMs in
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this way is, however, limited,32 and challenges with paper based
“top down” PROM capture include high rates of missing data
and lack of accessible feedback for use by clinicians and
patients.29
By contrast, using PROMs at the individual patient level is
relatively new. PROMs can be used to inform clinical decision
aids, for shared decision making, and to tailor care to individual
patient needs. Electronic capture of PROMs in clinic and
between appointments allows real time monitoring of symptoms,
flexible scheduling of hospital appointments in response to
PROM data, early detection of problems, and prompt clinical
intervention.33 A US randomised trial of web based symptom
monitoring in patients receiving chemotherapy showed that use
of the tool was associated with better quality of life, fewer
emergency hospital admissions, and increased survival.8 9 In
Denmark, the AmbuFlex telehealth system is being used to
schedule outpatient appointments for chronic conditions,
including asthma, chronic obstructive pulmonary disease,
epilepsy, sleep apnoea, and cancer.12 13 PROMs are completed
by patients at home and used for decision support to evaluate
the need for a consultation, reducing the need for unnecessary
outpatient appointments. To date, 31 000 outpatients have been
referred to AmbuFlex follow-up, and 115 000 telePRO based
contacts have been completed.
Challenges to consider
Several challenges have hindered both uptake and benefit to
patients of PROMs (box 1), with major problems found in
PROM study design, implementation, reporting, and
interpretation.26 PROM data collection is fragmented, with
limited coordination—if any—between teams responsible for
research and routine care. Clinical disciplines often lack a
standardised approach to assessment. Patients may be asked to
complete multiple questionnaires, often with overlapping items,
which can be burdensome and confusing. Furthermore, PROMs
are often poorly or not reported, which limits their effects on
patient care and is unethical.29 38 Evidence shows that clinicians
find that collecting PROMs improves clinical care and workflow
and is “beneficial rather than burdensome.”4 But some clinicians
think that these data are “subjective” and therefore biased or
unimportant compared with laboratory findings.
Box 1: Current challenges in PROM assessment
PROM selection
PROMs are not always designed and selected with patient input to ensure
that they measure what matters
Measurement properties, patient acceptability and burden, cultural validity,
and interpretation guidelines are not always considered
Inconsistency in PROMs used within and across disease specialties make
comparisons difficult
Ethical concerns
Patients may be unsure why they are being asked to complete a PROM,
who will access their responses, and how the data will be used
Patient burden of completing multiple questionnaires
Inconsistent management of situations where PROM data show
“concerning levels of psychological distress or physical symptoms that
may require an immediate response”34
Poor quality or no reporting of PROM data means that patients may
complete multiple questionnaires for no discernible purpose
Lack of PROM specific ethical guidance
Data collection, analysis, reporting, and interpretation
Engagement and acceptance from stakeholders for PROM collection may
be lacking
Many clinical trials do not provide a clear rationale for PROM assessment26
How the data will be used to maximise patient care has not always been
fully considered, even in routine clinical practice29
PROM data in research is commonly collected from a relatively small
subset of the population, hindering wider applicability of findings. This
may be more pronounced in trials with a “substudy” approach, or where
appropriate, culturally validated, alternative language PROMs are not
available
Missing data hinder reporting and use, and approaches to minimising
missing data are highly variable26
Lack of consensus regarding analytical approach35
Many clinical applications of PROMs have been developed in silos and
remain unpublished, limiting sharing of implementation strategies, good
practice, and results
PROM results are often poorly reported and are difficult to access and
interpret by patients and clinicians36
Data logistic problems
Incompatible IT systems without integration with electronic health records
and use across service providers
Data stored in different formats
Lack of relevant IT/health informatics expertise
Inefficient uncoordinated approach
Development in silos leads to duplication of effort and inconsistency in
collection methods, measures used, and data collected
Lack of integration between routine data collected for population level
initiatives and individual symptom monitoring, and between routinely
collected PROMs and research data
Missed opportunity to upscale datasets and enhance efficiency; no
opportunity to “collect once, use many times”37
Integrated approach to PROMs
We need a strategic, coordinated, integrated approach to PROM
assessment, a view supported by international qualitative
research.39 This approach should be aimed at creating a
non-burdensome pathway for patients to provide meaningful
PROM data that may be used to support shared decision making,
as well as provide a patient centred data pipeline for audit,
benchmarking, research, and real world evidence (fig 1). Routine
remote PROM monitoring could be used to support not only
patients at high risk of emergency admission but also the
millions of people who have multiple long term health
conditions to reduce unnecessary outpatient appointments,
promote medicine adherence, and tailor care to individual needs.
Beyond optimising healthcare resources, this approach offers
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broader benefits to patients and society, with potential reductions
in time off work, carer burden, and carbon footprint.
Crucially, the same PROM data could be aggregated to inform
commissioning and service delivery decisions. Concurrently,
the data could be incorporated into pragmatic trials to provide
real world evidence of effectiveness and safety. Large scale
“PROmic” data could be integrated with genomic, proteomic,
metabolomic, clinical, and biomarker data and be used in
prognostic models to inform patients of likely courses of
symptom burden and functioning.40
Integrative approaches to PROM assessment should consider
ways to reduce inefficiencies in data acquisition: a harmonised
approach to the selection, collection, analysis, and reporting of
PROMs, integration into the electronic health record, and
guidance on the optimal presentation and use of data (fig 2).
Stakeholder engagement and cooperation
A national PROM strategy should be developed with input from
patients, clinicians, academics, industry, regulators, ethicists,
and policy makers to ensure that the system and data meet
stakeholder needs. We have found that engagement from
patients, senior management, nurses, consultants, and allied
healthcare professionals is essential to successful delivery of
PROM specific strategic goals.10 13 29
Establish which outcomes to measure
PROMs should measure outcomes that correspond to stakeholder
needs. Identifying these outcomes and what matters to patients
should be a priority. Regulatory agencies may focus on physical
symptoms and functioning to inform licensing and labelling
claims, whereas patients and health policy makers may be more
interested in other domains of health related quality of life, such
as participation in social activities and emotional wellbeing.41
Stakeholder relevant PROMs can be identified through patient
involvement, qualitative research, or core outcome sets. These
provide a set of standardised outcomes to be assessed in routine
practice or effectiveness trials. They often include traditional
clinical outcomes, such as all cause mortality, alongside
measures of symptom burden, functioning, and disease control,
which can be measured using PROMs. Several core outcome
sets are available from the International Consortium for Health
Outcomes Measurement42 and the Core Outcome Measures in
Effectiveness Trials initiative43; further efficiencies may be
gained, however, if a single core outcome set can be generated
for research and routine practice for a clinical area or a broader
set of conditions, such as inflammatory diseases.
Selection of PROMs
Identifying and selecting valid, reliable tools that are acceptable
to patients from the target population may be challenging. The
Consensus Based Standards for the Selection of Health
Measurement Instruments initiative and the Evaluating the
Measurement of Patient Reported Outcomes programme provide
useful guidance to support the review of measurement
properties.44 45 Selected PROMs should have been developed
with patient input,27 but this is not the case for many commonly
used measures. A further challenge is the use of different
measurement scales, which make it difficult to compare across
measures. The Patient Reported Outcomes Measurement
Information System (PROMIS) aims to provide measures scored
on a common scale across global, physical, mental, and social
health domains. The PROMIS items can be used for
computerised adaptive testing to reduce patient burden.46 Further
benefits of PROMs may be realised through individualised
measures, but research in this area is scarce.32 Ultimately, the
utility of the measure may differ depending on context and
purpose, but wherever possible systems should be designed with
multiple use in mind.
Developing a governance framework
Patients need to know who will access their data and how their
data will be used. Clearly this has important consent implications
for integrative PROM collection, which must meet data
protection regulations. PROM data may reveal worrying levels
of psychological distress or physical symptoms that may require
an immediate response, known as a “PRO alert.”34 Clear
response pathways for the management of PRO alerts should
be in place, and issues around legal liability for failure to act
must be considered. Overarching guidance on governance would
help implementation of PROMs and promote efficiency in
delivery.
Integrated approach to electronic capture of
PROMs
Health informatics systems should be developed to capture
PROMs in a standardised way that will allow patients and
clinicians to access data at the point of care, incorporating
flexible permissions that allow the patient to choose how their
data will be used. National institutes for data science in
healthcare should play a pivotal role in infrastructure
developments. Operational and logistical matters—such as
patient identification, usability of the system by diverse patient
groups, automated reminders, algorithms for PROM alert
management, and reporting mechanisms—require careful
consideration to encourage compliance, ensure smooth
workflow, and promote data quality. To fully realise the benefits
and to meet multiple stakeholder needs, PROM data should be
aggregated with clinical and “omic” data; for example, to
facilitate case mix adjustment for comparison of service
providers and for use in prognostic models.40
Analysis, reporting, interpretation, and
dissemination of PROM data
Data will need to be analysed and reported using different
templates tailored to stakeholder needs. PROM data are currently
presented in a wide range of formats and further research is
needed to optimise their presentation for accurate interpretation
of the data and to make it useful.47 We have found that training
and support is needed during early adoption.
System evaluation
Integrating PROM data will require iterative development and
improvement. The cost effectiveness of PROM systems, impact
on workflow and user satisfaction, and potential biases
associated with multiple uses of data should be rigorously
assessed.48
Conclusions
Routine collection, processing, and sharing of PROMs may
offer huge benefits to society through better health outcomes
and use of resources. There is clearly much to do to maximise
the benefits of PROMs for patients and society. A crucial first
step is to establish a national multi-stakeholder steering group,
involving patients, clinicians, PROM methodologists, regulators,
policy makers, and NHS digital to standardise PROM data and
to establish and share knowledge and good practice. Integrated
approaches to data collection will help promote optimal efficient
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collection, reduce patient burden, and enable us to harness
patient centred data alongside health and biomedical outcomes
to tackle healthcare challenges at scale. Greater collaborative
multi-stakeholder efforts are required both nationally and
internationally for the benefits of PROMs to be realised.
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Table
Table 1| Use of PROM data by stakeholders, and current data collection
Data source/availability of
data
Main stakeholderExamplesUse of PROM data
Individual patient management:
Research/routinely collected
data when available
Patient/cliniciansPartners HealthCare has collected more than 1.2 million PROM
scores in 75 clinics across 21 specialties, including urology,
orthopaedics, psychiatry, and primary care, since 2012. Providers
have said that PROMs can improve physician satisfaction,
physician-patient relationships, shared decision making, and
workflow efficiency4
A US study of outcomes reported by patients (n=2013) undergoing
postmastectomy breast reconstruction using implant or autologous
Inform shared decision making
Tailor care to individual needs
techniques assessed patient psychosocial and sexual wellbeing
two years after surgery using the BREAST-Q PROM. Researchers
found that patients who underwent autologous reconstruction were
more satisfied and had greater wellbeing than those who chose
implant reconstruction.5
Research/routinely collected
data in specific
patient/population groups
Patients/cliniciansThe improving access to psychological therapies (IAPT) programme
has transformed treatment of adult anxiety disorders and depression
in England. Over 900 000 people access IAPT services each year.
The outcome monitoring system ensures that IAPT obtains symptom
scores before and after treatment, which are used to inform
treatment planning6
Screening/monitoring
Research/real time
monitoring in routine practice
(pockets of excellence but not
widespread)
Patient/cliniciansUsing health related quality of life assessments improved
patient-physician communication and enabled doctors to identify
a greater proportion of patients with moderate-to-severe health
problems in several domains, compared with standard care7
Facilitate communication
Research/real time
monitoring in routine
practice (pockets of
excellence but not
widespread)
Patient/cliniciansRemote symptom monitoring in patients receiving chemotherapy
at Memorial Sloan Kettering Cancer Centre reduced emergency
department admissions by 7%, hospital admissions by 4%, helped
patients stay on treatment longer, improved patient quality of life
by 31%, and increased survival on average by five months at low
cost.8 9
In the UK similar work is in development with current studies, for
example, in chronic kidney disease and cancer10 11
Facilitate early identification of
problems and improve patient
outcomes
Allow rapid referral to specialist
services when necessary
Currently not in widespread
use in UK
Patients/cliniciansAmbuflex telePRO system, Denmark: see main text12 13Reduce unnecessary outpatient
appointments for stable patients
Limited data availableService users/patientNHS PROMs programme: see main textInform choice of healthcare
provider
Research data when
available
Patient/clinicianThe multiple sclerosis impact scale 29 (MSIS-29) assesses quality
of life in people with multiple sclerosis. MSIS-29 scores are
associated with risk of 10 year mortality, even after adjusting for
known risk factors for mortality such as age, sex, and baseline
disability score14
Individual prognosis on symptom
and functioning
Population level health
management:
Research data when
available
Regulatory agencies
(patients/clinicians/policy
makers through subsequent
use)
The regulatory endpoints providing the basis for FDA approval of
ruxolitinib for intermediate or high risk myelofibrosis included an
improvement in symptoms measured with the modified Myelofibrosis
Symptom Assessment Form version 2.0 diary15
Patient focused drug and device
development to inform licensing
and labelling claims
Research data/routine
practice data when available
Patient/clinicians/policy
makers
In the CARE-HF trial, PROM data were used to measure the
effectiveness of cardiac resynchronisation, to assess the patient
journey and longer term effects of treatment, and to inform cost
effectiveness analyses and health technology appraisal16 17
Understanding short and longer
term effects of treatment
Research data when
available
Clinical guideline
developers/clinicians/patients
The European Society of Cardiology guidelines for the diagnosis
and treatment of acute and chronic heart failure recognise improving
quality of life as a key goal of treatment18
Inform clinical guidelines
Research/routine clinical data
when available
Service users/policy makersCommissioning groups have used PROM data from the Oxford
Knee Score to consider the subgroups of patients that may benefit
most from knee and hip replacement and varicose vein surgery.19
Inform commissioning
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Table 1 (continued)
Data source/availability of
data
Main stakeholderExamplesUse of PROM data
Research data when
available
Health technology assessment
agencies
A cost effectiveness analysis of the three most commonly chosen
types of prosthesis for total hip replacement showed that lifetime
Inform health technology
assessment/reimbursement
costs were generally lowest with cemented prostheses and that
postoperative quality of life and lifetime quality adjusted life years
were highest with hybrid prostheses20
Research data when
available (currently not
widespread)
Patients/service
managers/clinicians
The Mayo Clinic Cancer Center measured overall quality of life,
pain, and fatigue at over 30 000 clinical visits between 2010 and
2016. Between 20% and 50% of patients, depending on oncology
clinic, reported quality of life deficits and underwent clinical
interventions or treatment modifications as a result.21
Stratified care/integration with
other “omics”/big data
Research/real world data
when available
Service
users/researcher-policy maker
The Patient Reported Outcomes Safety Event Reporting Consortium
was convened to improve safety reporting by better incorporating
the patient perspective. “Real world” data from PROMs can
contribute important new knowledge about the benefits and risks
of drugs22
Protect patient safety through
postmarketing surveillance
Research or audit data when
available
Service users/service
manager
Aneurin Bevan University Health Board, Wales, has collected
PROMs across a range of clinical settings including irritable bowel
disease and Parkinson’s disease and is using the data to inform
service delivery and implement value based healthcare.23
Service improvement/value based
care
Audit dataService users/service
manager
NHS PROMs programme: see main text
National Quality Forum, US 24
Audit/benchmarking of providers
Audit dataService users/policy makersThe Quality and Outcomes Framework25Pay for performance
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Figures
Fig 1 Integrated assessment of PROMs to meet multiple stakeholder needs
Fig 2 Steps to realising a fully integrated PROM system
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